FDA blesses Genzyme's Mozobil; Undergrads use ADHD meds to study;

> Genzyme got the FDA nod for its stem cell transplant drug Mozobil and won special status protecting the treatment from competition for seven years. Release

> In a Duke study of undergraduates, 5 percent said they had used an ADHD medication like Ritalin or Adderall without a prescription in the past six months, with 90 percent of those using the drugs to help them study. Report

> Denmark's Lundbeck says it is ready to start Phase III trials for nalmefene, a drug designed to treat alcohol dependency. The developer says that it plans to recruit 1,800 patients for three late-stage studies. Report

> Watson Pharmaceuticals won FDA approval for its generic version of Razadyne ER, an Alzheimer's treatment sold by Johnson & Johnson. Report

> There's been a shakeup at the top at Titan Pharmaceuticals, which has been winding down its operations as it focuses on finding a partner or buyer for its assets. Report

> Dechra Pharmaceuticals is targeting the lucrative U.S. pet market after winning FDA approval to market Vetoryl, which treats Cushing's syndrome in dogs. Report

> A new flu season has arrived, and with it comes a spike in worries about the potential outbreak of bird flu in humans. Report

> Jazz Pharmaceuticals announced a reduction in force of 71 employees, or approximately 24 percent of its workforce, to lower operating expenses. Release

> Aegerion Pharmaceuticals has once again given up on its hopes for an IPO. The developer told the Wall Street Journal that "the window is closed." The IPO market, said CFO Will Lewis, "is just not available." Report

> Former Bristol-Myers Squibb CFO Andrew Bonfield has taken the same post with Cadbury. Report

> Add San Diego-based Adventrx to the list of biotech companies mulling strategic options. Those options include the sale of one or more of its development programs, finding a merger partner or "other transactions that maximize the value of company's assets." Report

> Treating advanced prostate cancer with radiation and hormone-blocking drugs cut the death rate in half in a study of Scandinavian men, researchers report. Report

And Finally... Where there's a will, there's a way: Thieves cut a hole in a California pharmacy's roof to steal Viagra. Report